Cassava Sciences, Inc. (SAVA) Stock Analysis

Why this analysis is different

• A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Cassava Sciences, Inc. (SAVA) Healthcare & Pipeline Overview

Cassava Sciences is a clinical-stage biotech firm targeting neurodegenerative diseases, primarily Alzheimer's. Their lead drug candidate, simufilam, is undergoing clinical trials, while SavaDx is being developed as a diagnostic tool. The company operates in a competitive biotech landscape focused on addressing unmet needs in neurological disorders.

What Is the Investment Thesis for SAVA?

Cassava Sciences presents a high-risk, high-reward investment opportunity within the biotechnology sector. The company's value is primarily tied to the clinical success of simufilam, its lead drug candidate for Alzheimer's disease. Positive Phase 3 trial results could lead to significant market capitalization growth, given the unmet need for effective Alzheimer's treatments. However, the company's lack of revenue and reliance on a single drug candidate introduce substantial risk. Investors should closely monitor clinical trial outcomes and regulatory developments. The company's market cap is $0.09B as of 2026-05-10.

Based on FMP financials and quantitative analysis

SAVA Key Highlights

Cassava Sciences is a clinical-stage biotechnology company focused on neurodegenerative diseases.

• The lead therapeutic product candidate, simufilam, has completed Phase 2b clinical trials.
• SavaDx is an investigational diagnostic product candidate, a blood-based biomarker/diagnostic to detect Alzheimer's disease.
• The company changed its name from Pain Therapeutics, Inc. to Cassava Sciences, Inc. in March 2019.
• Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.

Who Are SAVA's Competitors?

SAVA is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are SAVA's Key Strengths?

Focus on a significant unmet medical need (Alzheimer's disease).

• Proprietary drug candidate (simufilam) with a novel mechanism of action.
• Potential for a blood-based diagnostic test (SavaDx) for early Alzheimer's detection.

What Are SAVA's Weaknesses?

Clinical-stage company with no currently marketed products.

• High reliance on the success of a single drug candidate (simufilam).
• Limited financial resources compared to larger pharmaceutical companies.

What Could Drive SAVA Stock Higher?

Phase 3 clinical trial results for simufilam.

• Development and commercialization of SavaDx.
• Strategic partnerships and collaborations.
• Out-licensing or acquisition of simufilam or SavaDx.

What Are the Key Risks for SAVA?

Financial-distress signal — its Altman Z-Score of -8.03 sits in the distress zone (elevated bankruptcy risk).

• Negative return on equity (-58.8%) — the business is not currently generating profit on shareholder capital.
• Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
• Clinical trial failures or delays for simufilam.
• Regulatory setbacks or rejection of simufilam or SavaDx.
• Competition from other companies developing Alzheimer's treatments.
• Patent challenges or infringement.
• Limited financial resources.

What Are the Growth Opportunities for SAVA?

• Advancement of Simufilam through Phase 3 Clinical Trials: The successful completion of Phase 3 clinical trials for simufilam represents a major growth opportunity for Cassava Sciences. Positive results demonstrating significant efficacy in slowing or reversing cognitive decline in Alzheimer's patients could lead to regulatory approval and commercialization. This is an ongoing catalyst.
• Development and Commercialization of SavaDx: The development and commercialization of SavaDx, a blood-based diagnostic for Alzheimer's disease, presents another significant growth opportunity. An accurate and easily accessible diagnostic tool could revolutionize Alzheimer's diagnosis, enabling earlier intervention and treatment. The market for Alzheimer's diagnostics is growing, driven by the increasing prevalence of the disease and the need for early detection. This is an ongoing catalyst.
• Expansion into Other Neurodegenerative Diseases: Cassava Sciences could leverage its expertise and technology platform to expand into other neurodegenerative diseases beyond Alzheimer's. This could involve developing new therapies or diagnostics for conditions such as Parkinson's disease, Huntington's disease, or frontotemporal dementia. The market for neurodegenerative disease treatments is substantial, offering significant growth potential. This is a potential catalyst.
• Strategic Partnerships and Collaborations: Forming strategic partnerships and collaborations with larger pharmaceutical companies or research institutions could accelerate the development and commercialization of Cassava Sciences' products. These partnerships could provide access to funding, expertise, and distribution networks, enhancing the company's ability to bring its therapies to market. This is a potential catalyst.
• Out-Licensing or Acquisition of Simufilam or SavaDx: Cassava Sciences could explore the possibility of out-licensing or being acquired by a larger pharmaceutical company. This could provide a significant return on investment for shareholders, particularly if simufilam demonstrates strong clinical efficacy. The biotechnology industry is characterized by frequent mergers and acquisitions, with larger companies often acquiring smaller firms with promising drug candidates. This is a potential catalyst.

What Are SAVA's Competitive Advantages?

• Proprietary drug candidates with unique mechanisms of action.
• Patent protection for their drug candidates and diagnostic tools.
• Clinical data supporting the safety and efficacy of their products.
• Expertise in neurodegenerative disease research and development.

What Does SAVA Do?

Cassava Sciences, Inc., formerly known as Pain Therapeutics, Inc., was founded in 1998 and is headquartered in Austin, Texas. The company rebranded in March 2019 to reflect its strategic shift towards developing treatments for neurodegenerative diseases. Cassava Sciences is dedicated to developing innovative therapies for conditions like Alzheimer's disease, which currently lacks effective treatment options. Their primary focus is on simufilam, a proprietary small molecule drug designed to restore the normal shape and function of altered filamin A protein in the brain. This protein is believed to play a crucial role in Alzheimer's pathology. Simufilam has completed Phase 2b clinical trials, and the company is working towards further clinical development. In addition to simufilam, Cassava Sciences is developing SavaDx, a blood-based diagnostic test aimed at detecting Alzheimer's disease early. This diagnostic tool could potentially revolutionize Alzheimer's diagnosis by providing a less invasive and more accessible method for identifying the disease. Cassava Sciences operates within the highly competitive biotechnology industry, facing competition from larger pharmaceutical companies and other biotech firms also focused on neurodegenerative diseases. The company's success hinges on the successful clinical development and regulatory approval of simufilam and SavaDx.

What Products and Services Does SAVA Offer?

• Develop drugs for neurodegenerative diseases.
• Focus on Alzheimer's disease therapeutics.
• Develop simufilam, a small molecule drug for Alzheimer's.
• Develop SavaDx, a blood-based diagnostic for Alzheimer's disease.
• Conduct clinical trials to evaluate the safety and efficacy of their drug candidates.
• Seek regulatory approval for their products from agencies like the FDA.

How Does SAVA Make Money?

• Develop and patent novel drug candidates for neurodegenerative diseases.
• Conduct clinical trials to demonstrate safety and efficacy.
• Seek regulatory approval from health authorities.
• Potentially commercialize approved drugs directly or through partnerships.
• Generate revenue through drug sales, licensing agreements, or partnerships.

What Industry Does SAVA Operate In?

Cassava Sciences operates within the biotechnology industry, which is characterized by high research and development costs, lengthy regulatory approval processes, and intense competition. The Alzheimer's disease market, in particular, represents a significant opportunity due to the growing aging population and the lack of effective treatments. The competitive landscape includes major pharmaceutical companies and smaller biotech firms all vying to develop disease-modifying therapies. Success in this field requires strong scientific expertise, efficient clinical trial execution, and the ability to navigate the complex regulatory environment.

Who Are SAVA's Key Customers?

• Patients suffering from Alzheimer's disease.
• Healthcare providers who treat Alzheimer's patients.
• Pharmaceutical companies interested in licensing or acquiring their drug candidates.
• Research institutions involved in Alzheimer's disease research.

Wall Street analysts project Cassava Sciences, Inc. revenue of about $0 for fiscal 2026, with EPS near $-0.90.

SAVA Valuation & Market Position

With a $63.8M market cap, Cassava Sciences, Inc. sits in the micro-cap segment of the market. Relative to its peer group, SAVA's quantitative score of 47/100 is below the peer average of 76/100.

Return on equity for Cassava Sciences, Inc. stands at -58.8%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -40.7%, showing how much profit it generates from its asset base. Its free cash flow yield is -46.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 2.08 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -66.3%, the inverse of the P/E and a quick read on earnings relative to price.

Cassava Sciences, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -8.03 places it in the distress zone, a signal of elevated financial risk.

Cassava Sciences, Inc. has beaten Wall Street's EPS estimate in 5 of its last 8 reported quarters — more hits than misses. Reported results have landed about 41.9% below estimates on average.

Company Profile

Cassava Sciences, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Austin, US. The company is led by CEO Richard Jon Barry. SAVA has traded publicly since 2000.

SAVA Financials

SAVA Latest News

No recent news available for SAVA.

SAVA Analyst Consensus

SAVA MoonshotScore

What Investors Ask About Cassava Sciences, Inc. (SAVA) — Healthcare

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources